Prebiotic stachyose inhibits PRDX5 activity and castration-resistant prostate cancer development

By sjmartinez • August 22, 2024

Wang R, Pan Y, Zhang L, Wang J, Ni J, Ding Y, Wang S, Yin J, Ding L, Ran X, Fan S, Sun Q, Tan SY, Koeffler HP, Li J, Mi Y, Chen YQ. Prebiotic stachyose inhibits PRDX5 activity and castration-resistant prostate cancer development. Int J Biol Macromol. 2024 Aug 19:134844. doi: 10.1016/j.ijbiomac.2024.134844. Epub ahead of print. PMID: 39168191.

Tags: castration-resistant prostate cancer, Drug-tolerant persister, Hematology/Oncology, Nuclear factor erythroid 2-related factor 2, peroxiredoxin 5, Publications, stachyose, Stachyose caproate

Related Posts

Analyses of adverse events and patient-reported outcomes with the toxicity index in cancer clinical trials

Gresham G, Henry NL, Bandos H, Calsavara VF, Cecchini RS, Diniz MA, Hays RD, Luu M, Kim S, Rogatko A, Yothers G, Ganz PA, Tighiouart[...]

Anti-VEGF neutralizing antibody delays osteomucosal healing by reducing collagen formation in mice

Bae EB, Kim MY, Ji S, Cho IW, Kim SY, Esmaeili M, Baik SS, Kim S, Tetradis S, Park NH, Gwack Y, Kim RH. Anti-VEGF[...]

Collagen-binding IL-12-armoured STEAP1 CAR-T cells reduce toxicity and treat prostate cancer in mouse models

Sasaki K, Bhatia V, Asano Y, Bakhtiari J, Kaur P, Wang C, Matsuo T, Dubois O, Chiu PC, Gun D, Singh C, Panagi I, Noblecourt[...]